Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating)'s share price was up 10.3% during mid-day trading on Friday . The company traded as high as $12.99 and last traded at $12.89. Approximately 24,159 shares traded hands during trading, a decline of 93% from the average daily volume of 346,162 shares. The stock had previously closed at $11.69.

Kiniksa Pharmaceuticals Stock Up 14.7 %

The company has a market cap of $929.04 million, a PE ratio of -8.28 and a beta of -0.12. The stock's 50 day moving average is $9.96 and its 200-day moving average is $10.03.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Pictet Asset Management SA raised its stake in Kiniksa Pharmaceuticals by 6.4% during the fourth quarter. Pictet Asset Management SA now owns 3,548,649 shares of the company's stock valued at $41,768,000 after purchasing an additional 213,744 shares in the last quarter. BlackRock Inc. raised its stake in shares of Kiniksa Pharmaceuticals by 0.3% in the first quarter. BlackRock Inc. now owns 3,494,325 shares of the company's stock valued at $34,734,000 after acquiring an additional 10,473 shares during the period. Vanguard Group Inc. raised its stake in shares of Kiniksa Pharmaceuticals by 4.0% in the first quarter. Vanguard Group Inc. now owns 3,006,650 shares of the company's stock valued at $29,886,000 after acquiring an additional 115,942 shares during the period. Great Point Partners LLC raised its stake in shares of Kiniksa Pharmaceuticals by 108.3% in the first quarter. Great Point Partners LLC now owns 1,118,067 shares of the company's stock valued at $11,114,000 after acquiring an additional 581,329 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of Kiniksa Pharmaceuticals by 61.7% in the first quarter. Goldman Sachs Group Inc. now owns 936,604 shares of the company's stock valued at $9,310,000 after acquiring an additional 357,387 shares during the period. Hedge funds and other institutional investors own 42.57% of the company's stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Read More

• Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
• MarketBeat: Week in Review 8/1 – 8/5
• How to Use High Beta Stocks to Maximize Your Investing Profits
• Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
• Beyond Meat Is Not Beyond Hope, And It's Cheap
• Why Apple Could Be At All-Time Highs By Year End

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.